Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTY-101
- Development stage
- Phase 1
- Lead developer
- Century Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CNTY-101 is an investigational, off-the-shelf allogeneic cell therapy product composed of induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells engineered with a CD19-directed chimeric antigen receptor (CAR). It incorporates Century Therapeutics’ proprietary Allo-Evasion edits to overcome host versus graft rejection by targeting CD8+ T cells, CD4+ T cells, and NK cells. Additionally, CNTY-101 is engineered to express interleukin 15 (IL-15) for enhanced cytokine support, improving the persistence and functionality of the infused NK cells. The therapy is being developed primarily for relapsed or refractory B-cell Non-Hodgkin’s lymphoma and has also entered early-phase clinical development for autoimmune diseases such as systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis[1][2][3][4][5][6].
- Other names
- CD19-targeting iPSC-derived CAR-NK cellsCD-19-targeting iPSC-derived CAR-NK cellsCD 19-targeting iPSC-derived CAR-NK cells
02
Targets
Beyond the preview
Go deeper on CNTY-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTY-101.